Tempus AI, Inc.

Tempus AI, 10% owner, acquired 320,267 shares ($2.7M) across 12 purchases; stock now down 27.0% from 52-week high

Tempus AI, a 10% shareholder, completed 12 separate purchases totaling 320,267 shares for $2,739,181.17 between November 18 and December 22, 2025, at a blended average price of $8.55. The filing is material in scale (320.3K shares added; holdings now 13.04M shares), yet the timing raises concerns: the current price of $8.21 sits 27.0% below the 52-week high, and the stock has declined 11.7% over the past 30 days despite the acquisition activity. The insider's cross-ticker track record shows 0% win rate on 90-day holding periods, and the prior same-ticker trade at PSNL (August 2024 buy) was poorly timed, with a -15.2% return over 90 days. The company posted a $-21.7M net loss in the latest quarter and has been unprofitable over the full fiscal year, though revenue grew +15.2% annually, leaving investors to weigh near-term losses against top-line momentum.

Tempus AI (10% owner) purchases 3.5M PSNL shares for $17.7M, raising stake to 12.72M shares (+38.0%)

Tempus AI, already a substantial 10% owner, executed a major acquisition of 3,500,000 shares at $5.07, increasing holdings by 38.0% to 12,718,800 shares total for a transaction value of $17,745,000.00. This large-scale accumulation occurs in a company with revenue of $22,580,000.00 (latest quarter) but net income of $-12,802,000.00, alongside 13.0% annual revenue growth that has not yet translated to profitability. The stock has surged 47.8% over 30 days and 265.9% over 90 days from depressed levels, recently trading at $5.69 against a 52-week high of $5.99. The transaction signal—a major holder choosing to deploy substantial capital into a money-losing but growing-revenue biotech company amid significant recent price momentum—merits close attention to Tempus AI's strategic rationale, particularly given Personalis's unprofitability and whether this positioning reflects confidence in a near-term inflection or a longer-term turnaround thesis.